Cellular Immunotherapy Market Worth $37.97 Billion by 2030: Grand View Research, Inc.

News provided by

Jul 19, 2022, 08:30 ET

SAN FRANCISCO, July 19, 2022 /PRNewswire/ -- The global cellular immunotherapy market size is expected to reach USD 37.97 billion by 2030, according to a new report by Grand View Research, Inc. It is estimated to register a CAGR of 22.41% during the forecast period, driven by the growing government support for innovative therapies research, rising prevalence of cancer, development of advanced cell-based immunotherapies, and increasing R&D investment by global players.

Key Industry Insights & Findings from the report:

CAR T cell therapy segment contributed a significant revenue share of 71.6% in 2021. Factors such as approval of new drugs, patent protection, and a robust product pipeline are expected to drive the segment.
B-cell malignancy is the largest segment by indication in 2021 due to the high product penetration; BREYANZI and Yescarta are among the drugs that contribute to its high share.
Hospitals dominated the market in 2021 due to the availability of skilled healthcare practitioners in hospital settings and ease of reimbursement.
North America dominated the market in terms of revenue in 2021, owing to the availability of a well-established healthcare infrastructure, high per capita healthcare expenditure, and the increasing prevalence of cancer in the region.
Some of the key players in the market space are Gilead Sciences Inc. (Kite Pharma); Bristol-Myers Squibb Company; Novartis AG; F. Hoffmann-La Roche Ltd.; GlaxoSmithKline plc.; Merck KGaA; AstraZeneca; Celyad; Pfizer Inc.; Adicet Bio, Inc.; Johnson & Johnson; and Dendreon Pharmaceuticals LLC

Read 165-page market research report for more Insights, "Cellular Immunotherapy Market Size, Share & Trends Analysis Report By Therapy Type (CAR T Cell Therapy, Dendritic Cell Therapy), By Indication (B-cell Malignancies, Prostate Cancer), By End-use, By Region, And Segment Forecasts, 2022 - 2030, published by Grand View Research.

Cellular Immunotherapy Market Growth & Trends

Growing support from government organizations and research institutes including the National Cancer Institute (NCI) and Center of Excellence in Immunology (CEI) for cellular immunotherapies research is one of the major factors driving the market growth. For instance, the CEI pulls out experts from other institutes such as NCI and NIH to promote the growth of immunotherapy for the treatment of cancer. Also, the Surgery Branch of the National Cancer Institute's Center for Cancer Research (CCR) is committed to the innovation of novel immunotherapies for the treatment of cancer patients.

The rising number of M&As, collaborations, acquisitions, and funding is a major trend observed in the market. M&A and collaboration help companies expand their existing product portfolio and regional reach in a short period. For instance, in March 2021, TrakCel received funding from Labcorp and AmerisourceBergen for cellular therapy orchestration research and global expansion. Also, in April 2020, Kite (a Gilead Company) and Teneobio, Inc. entered into a license agreement through which Kite will receive exclusive rights to specific antibodies targeted to B-cell maturation antigen (BCMA). Thus, such M&A and collaborations are expected to boost the market growth.

A substantial number of cellular immunotherapy companies are engaged in new product launches, pertaining to licensing, collaborations, & acquisitions, and regional expansion. Some of the key companies in the market are Bristol-Myers Squibb Company; Novartis AG; Gilead Sciences Inc. (Kite Pharma); F. Hoffmann-La Roche Ltd.; and Johnson & Johnson. These companies are adopting various business models to gain a competitive advantage. For instance, in February 2021, Novartis secured approval for the first Australian commercial CAR-T manufacturing site for Kymriah. With this approval, the company would be able to develop Kymriah in Australia, thereby providing easy access to Australian patients.

The COVID-19 pandemic has had a high impact on the market. Owing to stringent regulations to curb the pandemic, a slowdown in clinical trials, approval of new drugs, and delayed cancer diagnosis have been observed, affecting the industry's growth amid the pandemic. However, in several countries, the effect of COVID-19 declined after the third quarter of 2021, which helped the market regain traction.

Cellular Immunotherapy Market Segmentation

Grand View Research has segmented the global cellular immunotherapy market based on therapy type, indication, end-use, and region:

Cellular Immunotherapy Therapy Market - Type Outlook (Revenue, USD Million, 2018 - 2030)

CAR T Cell Therapy
Dendritic Cell Therapy
NK Cell Therapy
TIL Therapy
Others

Cellular Immunotherapy Market - Indication Outlook (Revenue, USD Million, 2018 - 2030)

B-cell Malignancies
Prostate Cancer
Liver Cancer
Renal Cell Carcinoma
Others

Cellular Immunotherapy Market - End-use Outlook (Revenue, USD Million, 2018 - 2030)

Hospitals
Cancer Institutes
Others

Cellular Immunotherapy Market - Regional Outlook (Revenue, USD Million, 2018 - 2030)

North America

U.S.
Canada

Europe

Germany
U.K.
France
Italy
Spain
Russia

Asia Pacific

Japan
China
India
Australia
South Korea

Latin America

Brazil
Mexico
Argentina

Middle East and Africa (MEA)

South Africa
Saudi Arabia
UAE

List of Key Players in the Cellular Immunotherapy Market

Bristol-Myers Squibb Company
Novartis AG
Gilead Sciences Inc. (Kite Pharma)
F. Hoffmann-La Roche Ltd
Merck KGaA
GlaxoSmithKline plc.
AstraZeneca
Pfizer Inc.
Johnson & Johnson
Celyad
Adicet Bio, Inc.
Dendreon Pharmaceuticals LLC

Check out more related studies published by Grand View Research:

Glioblastoma Multiforme Treatment Market - The global glioblastoma multiforme treatment market size is expected to reach USD 4.2 billion by 2028, according to a new report by Grand View Research, Inc. It is expected to expand at a CAGR of 8.8% from 2021 to 2028. The market is driven by the rising prevalence of the disease and increasing approval for novel therapy and combination therapy.
Castrate-resistant Prostate Cancer Market - The global castrate-resistant prostate cancer market size is expected to reach USD 16.2 billion by 2027, according to a new report by Grand View Research, Inc. The market is expected to expand at a CAGR of 8.4% from 2020 to 2027. This growth is driven by the rising global burden of castrate-resistant prostate cancer and unhealthy lifestyle.
Allergy Immunotherapy Market - The global allergy immunotherapy market size is expected to reach USD 3.1 billion by 2027 registering a CAGR of 9.0%, according to a new report by Grand View Research, Inc. Rising prevalence of allergic conditions is expected to boost the market growth. According to the statistics published by the American Academy of Allergy, Asthma & Immunology (AAAAI), global prevalence of allergic rhinitis ranges from 10% to 30%. The disease affects 7.8% of the adult population in U.S. alone.

Browse through Grand View Research's Pharmaceuticals Industry Research Reports.

About Grand View Research

Grand View Research, U.S.-based market research and consulting company, provides syndicated as well as customized research reports and consulting services. Registered in California and headquartered in San Francisco, the company comprises over 425 analysts and consultants, adding more than 1200 market research reports to its vast database each year. These reports offer in-depth analysis on 46 industries across 25 major countries worldwide. With the help of an interactive market intelligence platform, Grand View Research Helps Fortune 500 companies and renowned academic institutes understand the global and regional business environment and gauge the opportunities that lie ahead.

Contact:

Sherry James
Corporate Sales Specialist, USA
Grand View Research, Inc.
Phone: 1-415-349-0058
Toll Free: 1-888-202-9519
Email: [email protected]
Web: https://www.grandviewresearch.com
Grand View Compass | Astra ESG Solutions
Follow Us: LinkedIn | Twitter